

2008: DIABETES DRUGS IN DEVELOPMENT

Hindsight is 20/20
Foresight is 1/10,000

II-beta hydroxysteroid dehydrogenase inhibitor - Bristol-Myers Squibb	
Bristol-Myers Squibb (Originator)	
Development Status	Indication
I	Diabetes mellitus
Insulin inhalation - Alkermes/Eli Lilly	
Alkermes (Originator)	
Eli Lilly (Licensee)	
Development Status	Indication
III	Diabetes mellitus
Insulin inhalation - Baxter/Healthcare	
Baxter Healthcare Corporation (Originator)	
Development Status	Indication
I	Diabetes mellitus
Insulin inhalation - Coremed	
Coremed (Originator)	
Development Status	Indication
I	Diabetes mellitus
Insulin inhalation - QDose	
QDose (Originator)	
Development Status	Indication
I	Diabetes mellitus
Insulin oral - Coremed	
Coremed (Originator)	
Development Status	Indication
I	Diabetes mellitus
Fast degradation inhaled insulin - Nektar Therapeutics	
Nektar Therapeutics (Originator)	
Development Status	Indication
I	Diabetes mellitus
Amylin Pharmaceuticals (Originator)	
Development Status	Indication
II	Type-2 diabetes mellitus
III	Type-2 diabetes mellitus
IV	Type-2 diabetes mellitus
GLY 230	
Exocell (Originator)	
Development Status	Indication
I	Diabetic complications
ATG 002	
Development Status	Indication
I	Diabetes mellitus
Insulin	
Amylin Pharmaceuticals (Originator)	
Development Status	Indication
II	Type-2 diabetes mellitus
III	Type-2 diabetes mellitus
Elexatide intranasal - Amylin/Nestec	
Amylin Pharmaceuticals (Originator)	
Development Status	Indication
I	Type-2 diabetes mellitus
Humalog AT - Amgen/Novartis/Eli Lilly	
Amylin Pharmaceuticals (Originator)	
Development Status	Indication
III	Type-2 diabetes mellitus
Insulin	
Amylin Pharmaceuticals (Originator)	
Development Status	Indication
II	Type-1 diabetes mellitus
GLY 230	
Exocell (Originator)	
Development Status	Indication
I	Diabetic complications
ATG 002	
Development Status	Indication
I	Diabetic foot ulcer
Fibroblast growth factor 1 - CardioVascular BioTherapeutics	
CardioVascular BioTherapeutics Inc (Originator)	
Development Status	Indication
I	Diabetic foot ulcer
GAM 501	
Tissue Repair Company (Originator)	
Development Status	Indication
II	Diabetic foot ulcer
Gentamicin implant - Innocoll	
Innocoll (Originator)	
Development Status	Indication
I	Diabetic foot ulcer
Pexigagan	
Genera Corporation (Originator)	
Development Status	Indication
III	Diabetic foot ulcer
Sonedenoson	
New York University (Originator)	
Development Status	Indication
II	Diabetic foot ulcer
Superoxide solution	
Oculus Innovative Sciences (Originator)	
Development Status	Indication
II	Diabetic foot ulcer
Talactoferrin alfa	

Agennix (Originator)	
Development Status	Indication
II	Diabetic foot ulcer
Vascular endothelial growth factor - Genentech	
Genentech (Originator)	
Development Status	Indication
II	Diabetic foot ulcer
Botulinum toxin A - Allergan	
Allergan (Originator)	
Development Status	Indication
Clinical	Diabetic gastroparesis
Metoclopramide rapidly disintegrating tablet - Salix Pharmaceuticals/Wilmington Pharmaceuticals	
Wilmington Pharmaceuticals LLC (Originator)	
Development Status	Indication
Preregistration	Diabetic gastroparesis
Mitencinal	
Chugal Pharmaceutical (Originator)	
Development Status	Indication
II	Diabetic gastroparesis
Aflibercept	
Regeneron Pharmaceuticals (Originator)	
Agennix (Originator)	
Development Status	Indication
II	Diabetic foot ulcer
Vascular endothelial growth factor - Genentech	
Genentech (Originator)	
Development Status	Indication
II	Diabetic foot ulcer
Metoclopramide rapidly disintegrating tablet - Salix Pharmaceuticals/Wilmington Pharmaceuticals	
Wilmington Pharmaceuticals LLC (Originator)	
Development Status	Indication
Preregistration	Diabetic gastroparesis
Mitencinal	
Chugal Pharmaceutical (Originator)	
Development Status	Indication
II	Diabetic gastroparesis
Aflibercept	
Regeneron Pharmaceuticals (Originator)	
Development Status	Indication
II	Diabetic neuropathies
Clopidine topical gel - Arcion Therapeutics	
Arcion Therapeutics (Originator)	
Development Status	Indication
II	Diabetic neuropathies
Dextromethorphan/quinidine	
Center for Neurologic Study (Originator)	
Development Status	Indication
III	Diabetic neuropathies
Gabapentin extended-release - Depomed	
Depomed (Originator)	
Development Status	Indication
II	Diabetic neuropathies
Lacosamide	
University of Houston (Originator)	
Development Status	Indication
Preregistration	Diabetic neuropathies
MCC 257	
Mitsubishi Pharma Corporation (Originator)	
Development Status	Indication
II	Diabetic neuropathies
Memantine	
Merz Pharma (Originator)	
Childrens Medical Center Corporation (Originator)	
Development Status	Indication
I	Diabetic macular oedema
Bevasiranib	
Opko Health (Originator)	
Development Status	Indication
II	Diabetic macular oedema
Fluocinolone acetonide ophthalmic - Alimera Sciences/pSivida	
pSivida Inc (Originator)	
Development Status	Indication
III	Diabetic macular oedema
ICO 007	
Isis Pharmaceuticals (Originator)	
Development Status	Indication
I	Diabetic macular oedema
Pegaptanib	
Gilead Sciences (Originator)	
OSI Pharmaceuticals (Licensee)	
Development Status	Indication
III	Diabetic macular oedema
Ruboxistaurin	
Eli Lilly (Originator)	
Alcon (Licensee)	
Development Status	Indication
III	Diabetic macular oedema
Sirolimus ophthalmic - MacuSight	
MacuSight (Originator)	
Development Status	Indication
I	Diabetic macular oedema

Triamcinolone acetonide ophthalmic - SurModics	
SurModics (Originator)	
Development Status	Indication
I	Diabetic macular oedema
Aliskiren	
Novartis (Originator)	
Development Status	Indication
III	Diabetic nephropathies
FG 3019	
FibroGen (Originator)	
Development Status	Indication
I	Diabetic nephropathies
PS 433540	
Bristol-Myers Squibb (Originator)	
Development Status	Indication
I	Diabetic nephropathies
Pyridoxamine	
BioStratum (Originator)	
Development Status	Indication
II	Diabetic nephropathies
Sulodexide	
Alfa Wassermann Inc (Originator)	
Development Status	Indication
III	Diabetic nephropathies
TPABC - Transtech Pharma	
Transtech Pharma (Originator)	
Development Status	Indication
II	Diabetic nephropathies
Exelixis (Originator)	
Development Status	Indication
II	Diabetic nephropathies
ABT 894	
Novartis (Originator)	
Development Status	Indication
II	Diabetic neuropathies
AGN 203816	
Allergan (Originator)	
ACADIA Pharmaceuticals (Originator)	
Development Status	Indication
II	Diabetic neuropathies
Forest Laboratories (Licensee)	
Allergan (Licensee)	
Development Status	Indication
III	Diabetic neuropathies
Mexiletine	
Boehringer Ingelheim (Originator)	
Development Status	Indication
III	Diabetic neuropathies
QR 333	
Quigley Pharma (Originator)	
Development Status	Indication
II	Diabetic neuropathies
Ranirestat	
Dainippon Sumitomo Pharma (Originator)	
Development Status	Indication
III	Diabetic neuropathies
SB 509	
Sangamo BioSciences (Originator)	
Development Status	Indication
II	Diabetic neuropathies
TAK 428	
Takeda (Originator)	
Development Status	Indication
II	Diabetic neuropathies
TAK 583	
Takeda (Originator)	
Development Status	Indication
III	Diabetic neuropathies
Taperator controlled release	
Grünenthal (Originator)	
Ortho-McNeil (Licensee)	
Development Status	Indication
III	Diabetic neuropathies
Topiramate	
Johnson & Johnson Pharmaceutical Research & Development LLC (Originator)	
Development Status	Indication
III	Diabetic neuropathies
Diabetic retinopathy therapeutic - VitreoRetinal Technologies	
VitreoRetinal Technologies (Originator)	
Development Status	Indication
III	Diabetic retinopathy
Pegaptanib	
Gilead Sciences (Originator)	
OSI Pharmaceuticals (Licensee)	
Development Status	Indication
III	Diabetic retinopathy
Ruboxistaurin	
Eli Lilly (Originator)	
Alcon (Licensee)	
Development Status	Indication
Preregistration	Diabetic retinopathy

Abbott Laboratories • Amgen Inc. • Amylin Pharmaceuticals, Inc.
 • Astellas Pharma US, Inc • AstraZeneca Pharmaceuticals •
 • Eli Lilly and Company • GlaxoSmithKline • Johnson & Johnson
 • Novartis Pharmaceuticals Corp. • Pfizer, Inc. • Roche
 • sanofi-aventis Group • Takeda Pharmaceuticals •
 TAP Pharmaceuticals, Inc. • Wyeth



www.nyhpc.org
518-452-1137

Only one out of 10,000 potential medicines investigated by America's research-based biopharmaceutical companies makes it through the exacting quest of research and development to be approved for patient use by the Food and Drug Administration. Very long odds. But we see it through, and make the billions in investments, to save lives and improve the very quality of life for millions.

With hindsight, making a medicine may appear rather easy to some. But nothing could blur the truth more. **Discovery demands the focused, consummate expertise of tens of thousands of skilled scientists, support staff and state-of-the-art labs.** It is all essential to sustain the flow of new treatments for you, your children, grandchildren and generations to come. As a demonstration, we thought you would be interested to see the magnitude of the more promising Diabetes compounds that are currently under sharp scrutiny – some to advance from the exceptional foresights of today to the commonly seen **miracles of tomorrow.**

